1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > EpiCast Report: Prostate Cancer - Epidemiology Forecast to 2023

EpiCast Report: Prostate Cancer - Epidemiology Forecast to 2023

Summary

Prostate cancer is a malignant tumor that forms in the tissues of the prostate, a gland in the male reproductive system found below the bladder and in front of the rectum. Although prostate cancer cases have been reported in all age groups, the majority of cases occur in men over the age of 65 years. Prostate cancer is the second most common cancer in men worldwide. An estimated 1.1 million men worldwide were diagnosed with prostate cancer in 2012, accounting for 15% of all the cancers diagnosed in men (IARC, 2014).

This report provides an overview of the risk factors, comorbidities, and the global and historical trends for prostate cancer in the nine major markets (9MM) (US, France, Germany, Italy, Spain, UK, Japan, Brazil, and Canada). It includes a 10-year epidemiological forecast for the diagnosed incident cases of prostate cancer segmented by age (in 10-year age groups beginning at age 40 years and ending at age =85 years) in these markets.

In 2013, there were a total of 813,462 diagnosed incident cases of prostate cancer in the 9MM. GlobalData epidemiologists forecast that the diagnosed incident cases in the 9MM will increase to 1,106,349 cases by 2023 at an Annual Growth Rate (AGR) of 3.60%. All markets will see an increase in the number of cases, with AGRs ranging from 0.71% (Germany) to 8.66% (Brazil). The 9MM had an estimated 3,381,581 diagnosed five-year prevalent cases of prostate cancer in 2013. The number of diagnosed five-year prevalent cases will increase over the next decade to 4,618,451 diagnosed prevalent cases by 2023 at an AGR of 3.66%.

Brazil appears to be a market of concern, with a rapidly increasing incidence and prevalence of prostate cancer. GlobalData epidemiologists calculated that Brazil will have the highest AGR in diagnosed incident cases among the 9MM (8.66%), as well as the highest AGR in five-year diagnosed prevalent cases (8.98%).

Scope

- The Prostate Cancer EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for prostate cancer in the nine major markets (9MM) (US, France, Germany, Italy, Spain, UK, Japan, Brazil, and Canada). It includes a 10-year epidemiological forecast for the diagnosed incident cases of prostate cancer segmented by age (in 10-year age groups beginning at age 40 years and ending at age =85 years) and clinical stage at diagnosis in these markets. The report also provide a forecast for the diagnosed five-year prevalent cases of prostate cancer segmented by castration resistance status and bone metastases status.
- The prostate cancer epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 9MM.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global prostate cancer market.
- Quantify patient populations in the global prostate cancer market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and clinical stage at diagnosis that present the best opportunities for prostate cancer therapeutics in each of the markets covered.

Table Of Contents

EpiCast Report: Prostate Cancer - Epidemiology Forecast to 2023
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Related Report 9
3 Epidemiology 10
3.1 Disease Background 10
3.2 Risk Factors and Comorbidities 11
3.3 Global Trends 13
3.3.1 US 14
3.3.2 5EU 15
3.3.3 Japan, Brazil, and Canada 15
3.4 Forecast Methodology 16
3.4.1 Sources Used 17
3.4.2 Sources Not Used 23
3.4.3 Forecast Assumptions and Methods 24
3.5 Epidemiological Forecast for Prostate Cancer (2013-2023) 27
3.5.1 Diagnosed Incident Cases of Prostate Cancer 27
3.5.2 Age-Specific Diagnosed Incident Cases of Prostate Cancer 29
3.5.3 Age-Standardized Diagnosed Incidence of Prostate Cancer 31
3.5.4 Clinical Stage at Diagnosis 33
3.5.5 Diagnosed Five-Year Prevalent Cases of Prostate Cancer 34
3.5.6 Diagnosed Five-Year Prevalent Cases of CRPC 35
3.5.7 Diagnosed Five-Year Prevalent Cases of Bone Metastases Among CRPC Patients 37
3.6 Discussion 39
3.6.1 Epidemiological Forecast Insight 39
3.6.2 Limitations of the Analysis 40
3.6.3 Strengths of the Analysis 41
4 Appendix 42
4.1 Bibliography 42
4.2 About the Authors 47
4.2.1 Epidemiologists 47
4.2.2 Reviewers 47
4.2.3 Global Director of Therapy Analysis and Epidemiology 48
4.2.4 Global Head of Healthcare 49
4.3 About GlobalData 50
4.4 About EpiCast 50
4.5 Disclaimer 51

1.1 List of Tables
Table 1: Risk Factors and Comorbidities for Prostate Cancer 12
Table 2: 9MM, Sources of Prostate Cancer Diagnosed Incidence Data 17
Table 3: 9MM, Sources of Data for the Clinical Stage of Prostate Cancer at Diagnosis 18
Table 4: 9MM, Sources of Prostate Cancer Diagnosed Five-Year Prevalent Cases Data 19
Table 5: 9MM, Sources of CRPC Diagnosed Five-Year Prevalent Cases Data 20
Table 6: 9MM, Diagnosed Incident Cases of Prostate Cancer, Ages ?40 Years, N, 2013-2023 28
Table 7: 9MM, Age-Specific Diagnosed Incident Cases of Prostate Cancer, N, Row (%), 2013 30
Table 8: 9MM, Diagnosed Five-Year Prevalent Cases of Prostate Cancer, Ages ?40 Years, 2013-2023 34
Table 9: 9MM, Diagnosed Five-Year Prevalent Cases of CRPC, Ages ?40 Years, 2013-2023 36
Table 10: 9MM, Diagnosed Five-Year Prevalent Cases of Bone Metastases Among CRPC Patients, Ages ?40 Years, 2013-2023 38

1.2 List of Figures
Figure 1: 9MM, Historical Age-Standardized Prostate Cancer Diagnosed Incidence (Cases per 100,000 Population), 1998-2007 14
Figure 2: 9MM, Diagnosed Incident Cases of Prostate Cancer, Ages ?40 Years, N, 2013-2023 29
Figure 3: 9MM, Age-Specific Diagnosed Incident Cases of Prostate Cancer, N, 2013 31
Figure 4: 9MM, Age-Standardized Diagnosed Incidence of Prostate Cancer, Ages ?40 Years, 2013 32
Figure 5: 9MM, Percentage Distribution of Incident Cases of Prostate Cancer By Clinical Stage at Diagnosis, Ages ?40 Years 33
Figure 6: 9MM, Diagnosed Five-Year Prevalent Cases of Prostate Cancer, Ages ?40 Years, 2013-2023 35
Figure 7: 9MM, Diagnosed Five-Year Prevalent Cases of CRPC, Ages ?40 Years, 2013-2023 37
Figure 8: 9MM, Diagnosed Five-Year Prevalent Cases of Bone Metastases Among CRPC Patients, Ages ?40 Years, 2013-2023 38

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Prostate Cancer: Analytical Tool

Prostate Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Epiomic Epidemiology Series: Prostate Cancer Forecast in 18 Major Markets 2016-2026

Epiomic Epidemiology Series: Prostate Cancer Forecast in 18 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • September 2016
  • by Black Swan Analysis Ltd132

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Prostate Cancer in 18 Major Markets Prostate cancer is one of the most common cancers in men. The prostate, found only in men, is the ...

Prostate cancer- Market Insights, Epidemiology and Market Forecast-2023

Prostate cancer- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Prostate cancer - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.